NasdaqGS:BCEL

Stock Analysis Report

Executive Summary

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Atreca's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BCEL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.4%

BCEL

1.1%

US Biotechs

0.9%

US Market


1 Year Return

n/a

BCEL

9.1%

US Biotechs

15.5%

US Market

Return vs Industry: Insufficient data to determine how BCEL performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how BCEL performed against the US Market.


Shareholder returns

BCELIndustryMarket
7 Day-9.4%1.1%0.9%
30 Day0.7%10.4%4.7%
90 Day-47.7%5.8%6.6%
1 Yearn/a10.1%9.1%18.1%15.5%
3 Yearn/a16.0%12.3%48.0%38.5%
5 Yearn/a4.5%-0.4%62.1%44.2%

Price Volatility Vs. Market

How volatile is Atreca's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atreca undervalued compared to its fair value and its price relative to the market?

1.42x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BCEL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BCEL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BCEL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BCEL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BCEL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BCEL is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (2.8x).


Next Steps

Future Growth

How is Atreca forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-20.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCEL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCEL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCEL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if BCEL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BCEL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCEL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Atreca performed over the past 5 years?

-68.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: BCEL has high quality earnings.

Growing Profit Margin: BCEL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if BCEL's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare BCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).


Return on Equity

High ROE: BCEL has a negative Return on Equity (-28.95%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Atreca's financial position?


Financial Position Analysis

Short Term Liabilities: BCEL's short term assets ($206.5M) exceeds its short term liabilities ($7.5M)

Long Term Liabilities: BCEL's short term assets ($206.5M) exceeds its long term liabilities (183.0K)


Debt to Equity History and Analysis

Debt Level: BCEL is debt free.

Reducing Debt: BCEL has not had any debt for past 5 years.


Balance Sheet

Inventory Level: BCEL has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BCEL's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCEL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BCEL has sufficient cash runway for 2.944247 years if free cash flow continues to reduce at historical rates of -37.7% each year.


Next Steps

Dividend

What is Atreca's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BCEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BCEL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BCEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Atreca's salary, the management and board of directors tenure and is there insider trading?

1.6yrs

Average management tenure


CEO

John Orwin (54yo)

1.6yrs

Tenure

US$4,615,532

Compensation

Mr. John A. Orwin has been President, Chief Executive Officer and Director at Atreca, Inc. since April 19, 2018 Mr. Orwin has been a Director of Relypsa, Inc since June 2013 and Seattle Genetics, Inc. sinc ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD4.62M) is above average for companies of similar size in the US market ($USD1.15M).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.


Management Age and Tenure

1.6yrs

Average Tenure

55yo

Average Age

Experienced Management: BCEL's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Age and Tenure

2.5yrs

Average Tenure

61yo

Average Age

Experienced Board: BCEL's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: BCEL only recently listed within the past 12 months, with total shares outstanding growing by 344.3% in the past year..


Management Team

  • John Orwin (54yo)

    President

    • Tenure: 1.6yrs
    • Compensation: US$4.62m
  • Herb Cross (47yo)

    Chief Financial Officer

    • Tenure: 0.8yrs
  • Tito Serafini (56yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: US$2.60m
  • Paulette Dillon (57yo)

    Senior Vice President

    • Tenure: 0yrs
  • Guy Cavet (45yo)

    Chief Technical Officer

    • Tenure: 5.3yrs
  • Daniel Emerling

    Senior Vice President of Research

    • Tenure: 0yrs
  • Wayne Volkmuth

    Senior Vice President of Informatics and Information Technology

    • Tenure: 0yrs
  • Yann Tan

    Chief Technologist

    • Tenure: 0yrs
  • Norm Greenberg (59yo)

    Chief Scientific Officer

    • Tenure: 4.5yrs
    • Compensation: US$800.69k
  • Courtney Phillips

    General Counsel

    • Tenure: 0.3yrs

Board Members

  • Brian Atwood (66yo)

    Chairman of the Board

    • Tenure: 5.9yrs
    • Compensation: US$35.00k
  • John Orwin (54yo)

    President

    • Tenure: 1.6yrs
    • Compensation: US$4.62m
  • Larry Steinman (71yo)

    Chairman of External Scientific Advisory Board & Technical Advisor

    • Tenure: 0.3yrs
    • Compensation: US$150.00k
  • Franklin Berger (70yo)

    Independent Director

    • Tenure: 5.1yrs
    • Compensation: US$25.00k
  • Tito Serafini (56yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: US$2.60m
  • Bill Robinson (51yo)

    Director

    • Tenure: 0yrs
    • Compensation: US$250.00k
  • David Lacey (67yo)

    Independent Director

    • Tenure: 3.5yrs
  • Douglas Crawford

    Board Observer

    • Tenure: 0yrs
  • Andrew Farnum

    Board Observer

    • Tenure: 0yrs
  • Lindsey Rolfe (51yo)

    Director

    • Tenure: 0.3yrs

Company Information

Atreca, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atreca, Inc.
  • Ticker: BCEL
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$291.911m
  • Shares outstanding: 27.96m
  • Website: https://www.atreca.com

Number of Employees


Location

  • Atreca, Inc.
  • 500 Saginaw Drive
  • Redwood City
  • California
  • 94063
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCELNasdaqGS (Nasdaq Global Select)YesClass A Common StockUSUSDJun 2019
0C1MUN (Boerse Muenchen)YesClass A Common StockDEEURJun 2019
0C1DB (Deutsche Boerse AG)YesClass A Common StockDEEURJun 2019

Biography

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/19 01:06
End of Day Share Price2019/11/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.